Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study

David Lang,Florian Huemer,Gabriel Rinnerthaler,Andreas Horner,Romana E. Wass,Elmar Brehm,Kaveh Akbari,Marcel Granitz,Georg Hutarew,Bernhard Kaiser,Richard Greil,Bernd Lamprecht

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study

2019

David Lang
Florian Huemer
Gabriel Rinnerthaler
Andreas Horner
Romana E. Wass
Elmar Brehm
Kaveh Akbari
Marcel Granitz
Georg Hutarew
Bernhard Kaiser
Richard Greil
Bernd Lamprecht

Background Evidence on PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) therapy for advanced non-small-cell lung cancer (NSCLC) is mainly based on clinical trials in first- or second-line settings.

Keywords:

Cohort study
Oncology
PD-L1 inhibitor
Immune checkpoint
Clinical trial
Medicine
Immunology
Lung cancer
Cell
Internal medicine
ECOG Performance Status
Atezolizumab
Pembrolizumab
Pharmacology
Nivolumab
Performance status
Response Evaluation Criteria in Solid Tumors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations